Every material Form 8-K Jade Biosciences, Inc. has filed with the SEC since July 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Jade Biosciences announced preclinical data for JADE301, its anti-interferon beta antibody being developed for dermatomyositis, a rare autoimmune disease. The company said the data show high-affinity IFN-ß neutralization, a longer half-life than a dazukibart comparator, and good nonclinical tolerability, and it expects to start a Phase 1 trial in the fourth quarter of 2026.
JADE301 binds IFN-ß with a K D of 11.3 pM, about 2.5-fold higher affinity than the dazukibart comparator.
Non-human primate half-life is about 30 days after IV dosing, roughly 3-fold longer than the comparator.
Planned placebo-controlled Phase 1 trial in 24 healthy volunteers to start in Q4 2026, with interim data expected in the second half of 2027.
Jade Biosciences reported a second-quarter 2026 net loss of $55.8 million, up from $32.1 million a year earlier, as research and development and general and administrative expenses rose. The company said its $461.2 million in cash, cash equivalents and investments should fund operations into the fourth quarter of 2028, and it outlined pipeline timelines for JADE101, JADE201 and JADE301.
Net loss was $55.8 million for the quarter ended June 30, 2026, compared with $32.1 million a year earlier.
R&D expenses were $50.1 million, up from $22.5 million, and G&A expenses were $8.9 million, up from $5.2 million.
Cash, cash equivalents and investments were $461.2 million as of June 30, 2026, versus $336.2 million at December 31, 2025.
The company completed a $172.5 million public offering and expects its Phase 3 JADE101 trial to begin in the first half of 2027, pending FDA feedback.
Jade Biosciences entered into a license agreement with Paragon Therapeutics on June 29, 2026, granting it exclusive worldwide rights to certain monospecific antibodies and products targeting an undisclosed target. The company must pay Paragon milestone payments of up to $22.0 million, sublicensing fees of up to approximately $20.1 million, and royalties on net sales, which shows the financial commitments tied to the program.
Agreement dated June 29, 2026; Jade already paid a $1.5 million candidate nomination fee in January 2026.
Milestones total up to $22.0 million, including a $2.5 million payment upon first human dosing in a Phase 1 trial.
Royalties of low to mid-single-digit percentage on monospecific product sales and mid-single-digit on multispecific product sales.
Paragon will not run new campaigns generating monospecific antibodies against the Target for at least five years; full text to be filed with the 10-Q for the quarter ending June 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Jade Biosciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →